» Articles » PMID: 25238207

Cortisol As a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas

Overview
Specialty Endocrinology
Date 2014 Sep 20
PMID 25238207
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Incidental benign adrenocortical adenomas, adrenal incidentalomas are found in 4.5% of abdominal computed tomography scans, with the incidence increasing to 10% in patients older than 70 years of age. These incidentalomas frequently show evidence of excess cortisol secretion but without overt Cushing's syndrome. The mortality rate is increased in Cushing's syndrome.

Objective: This study sought to investigate whether patients with adrenal incidentalomas have an increased mortality.

Design: This was a retrospective, longitudinal cohort study.

Setting: The study was carried out in an Endocrine Investigation Unit in a University Teaching Hospital.

Patients: Two hundred seventy-two consecutive patients with an incidental adrenal mass underwent a dedicated diagnostic protocol, which included dexamethasone testing for hypercortisolism between 2005 and 2013. Overall survival was assessed in 206 patients with a benign, adrenocortical adenoma.

Main Outcome Measures: Survival analysis was carried out by using Kaplan-Meier curves and the effect of dexamethasone cortisol estimated by Cox-regression analysis. Cause-specific mortality was ascertained from death certificates and compared with local and national data.

Results: Eighteen of 206 patients died and the mean time (SD) from diagnosis to death was 3.2 (1.7) years. Seventeen of 18 patients who died had a post dexamethasone cortisol >1.8 μg/dL and there was a significant decrease in survival rate with increasing dexamethasone cortisol levels (P = .001). Compared with the <1.8 μg/dL group, the hazard ratio (95% confidence interval) for the 1.8-5 μg/dL group was 12.0 (1.6-92.6) whereas that of the >5 μg/dL group was 22.0 (2.6-188.3). Fifty percent and 33% of deaths were secondary to circulatory or respiratory/infective causes, respectively.

Conclusions: PATIENTS with adrenal incidentalomas and a post-dexamethasone serum cortisol >1.8 μg/dL have increased mortality, mainly related to cardiovascular disease and infection.

Citing Articles

Triglyceride-glucose index in patients with non-functioning adrenal incidentaloma, cortisol-secreting adrenal incidentaloma and healthy controls.

Meric C, Tasci I, Akin S, Candemir B, Guzel Esen S, Dag Z Am J Transl Res. 2024; 16(11):6679-6688.

PMID: 39678618 PMC: 11645597. DOI: 10.62347/JTQX7232.


A novel model using leukocytes to differentiating mild autonomous cortisol secretion and non-functioning adrenal adenoma.

Zhao X, Zhou J, Lyu X, Li Y, Ma L, Liu Y Sci Rep. 2024; 14(1):23557.

PMID: 39384846 PMC: 11464552. DOI: 10.1038/s41598-024-74452-y.


Cardiometabolic comorbidities and cardiovascular events in "non-functioning" adrenal incidentalomas: a systematic review and meta-analysis.

Favero V, Parazzoli C, Bernasconi D, Chiodini I J Endocrinol Invest. 2024; 47(12):2929-2942.

PMID: 39347906 PMC: 11549128. DOI: 10.1007/s40618-024-02440-0.


The Incidence of Cancers in Patients With Nonfunctional Adrenal Tumors: A Swedish Population-Based National Cohort Study.

Patrova J, Mannheimer B, Larsson M, Lindh J, Falhammar H J Endocr Soc. 2024; 8(10):bvae154.

PMID: 39301313 PMC: 11411210. DOI: 10.1210/jendso/bvae154.


Evaluating the efficacy of surgical and conservative approaches in mild autonomous cortisol secretion: a meta-analysis.

Ren X, Nan M, Zhang X Front Endocrinol (Lausanne). 2024; 15():1399311.

PMID: 39086899 PMC: 11288901. DOI: 10.3389/fendo.2024.1399311.


References
1.
Vogelzangs N, Beekman A, Milaneschi Y, Bandinelli S, Ferrucci L, Penninx B . Urinary cortisol and six-year risk of all-cause and cardiovascular mortality. J Clin Endocrinol Metab. 2010; 95(11):4959-64. PMC: 2968721. DOI: 10.1210/jc.2010-0192. View

2.
Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M . Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013; 169(5):715-23. DOI: 10.1530/EJE-13-0569. View

3.
Chiodini I, Mascia M, Muscarella S, Battista C, Minisola S, Arosio M . Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann Intern Med. 2007; 147(8):541-8. DOI: 10.7326/0003-4819-147-8-200710160-00006. View

4.
Lindholm J, Juul S, Jorgensen J, Astrup J, Bjerre P, Feldt-Rasmussen U . Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001; 86(1):117-23. DOI: 10.1210/jcem.86.1.7093. View

5.
Toniato A, Merante-Boschin I, Opocher G, Pelizzo M, Schiavi F, Ballotta E . Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg. 2009; 249(3):388-91. DOI: 10.1097/SLA.0b013e31819a47d2. View